Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tietz

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Hepatology (Baltimore, Md.)|March 3, 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinMoises Diago, Mitchell L Shiffman, Jean-Pierre Bronowicki, et al.
Scientific Reports|April 5, 2023
NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settingsJörn M Schattenberg, Maria-Magdalena Balp, Brenda Reinhart, et al.
Journal of the American Medical Informatics Association : JAMIA|March 8, 2021
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitisMatt Docherty, Stephane A Regnier, Gorana Capkun, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Annals of Internal Medicine|April 22, 2009
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trialDonald M Jensen, Patrick Marcellin, Bradley Freilich, et al.
Open Forum Infectious Diseases|June 10, 2024
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 StudyJeff Kingsley, Nagalingeswaran Kumarasamy, Luis Abrishamian, et al.
The Lancet. Infectious Diseases|October 10, 2025
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)Sophie Yacoub, Anastasia Demidova, Xin Hui S Chan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Hepatology (Baltimore, Md.)|March 3, 2010
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirinMoises Diago, Mitchell L Shiffman, Jean-Pierre Bronowicki, et al.
Scientific Reports|April 5, 2023
NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settingsJörn M Schattenberg, Maria-Magdalena Balp, Brenda Reinhart, et al.
Journal of the American Medical Informatics Association : JAMIA|March 8, 2021
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitisMatt Docherty, Stephane A Regnier, Gorana Capkun, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Annals of Internal Medicine|April 22, 2009
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trialDonald M Jensen, Patrick Marcellin, Bradley Freilich, et al.
Open Forum Infectious Diseases|June 10, 2024
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 StudyJeff Kingsley, Nagalingeswaran Kumarasamy, Luis Abrishamian, et al.
The Lancet. Infectious Diseases|October 10, 2025
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)Sophie Yacoub, Anastasia Demidova, Xin Hui S Chan, et al.
Pageof 2